Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Caforio takes CEO role as BMS faces tough year with promising new drugs

Trained in his native Italy as a doctor, Giovanni Caforio speaks not only English and Italian, but also Spanish, French and Portuguese. As he steps into the CEO role today at Bristol-Myers Squibb, the question will be how well he speaks dollars and cents.

Canon appoints Tanaka as CEO, president of U.S. subsidiary

Canon's American unit, Canon U.S.A., said it has appointed Akiko Tanaka to be both CEO and president of its wholly owned subsidiary, Canon U.S. Life Sciences.

COO Schultz out of a job after Novo's executive shuffle

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Ex-Sanofi exec Whitaker lands at Valeant in EVP role

After departing from Sanofi last year for the CEO's chair at Synta Pharmaceuticals, Anne Whitaker is now moving on to Valeant, where she'll step into the role of EVP and group chairman.

After topping Q1 estimates, Valeant hikes guidance on Salix buy

Following the fold-in of its recent $11.1 billion pickup of Salix Pharmaceuticals, on Wednesday, Valeant raised both its profit and revenue forecasts for the year. But things are already looking good for the Canadian drugmaker, which topped analyst estimates in both categories for Q1.

Activists get their way as Ariad CEO Berger steps down

Activist investor Alex Denner has called off his proxy fight with Ariad Pharmaceuticals, a cease-fire that appears to have cost Harvey Berger, the biotech's founder and CEO, his job.

Keryx selects John Neylan for newly created CMO role

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Allergan to cut loose 577 more workers in Irvine

The pink slips are flying at Allergan once again. Recently bought by Actavis in a $66 billion deal, the company is preparing to lay off 577 more workers in a cost-cutting drive that started last year and won't end till its new head honchos finish squeezing savings out of the combined company.

Drew Fromkin tapped to lead Langer's Blend Therapeutics

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Jeremy Levin's back, building a rare-disease biotech with failed drugs

Former Teva CEO Jeremy Levin has taken the pilot's seat at a stealth biotech devoted to rare brain diseases and is piloting a course straight into the industry spotlight.